Skip to main content
Erschienen in: Annals of Surgical Oncology 11/2014

01.10.2014 | Colorectal Cancer

Systematic Review of FDG-PET Prediction of Complete Pathological Response and Survival in Rectal Cancer

verfasst von: Sameer Memon, FRACS, A. Craig Lynch, MMedSci, FRACS, FCSSANZ, FASCRS (INT), Timothy Akhurst, MD, MBBS, Samuel Y. Ngan, MBBS, Satish K. Warrier, MS, FRACS, Michael Michael, MD, FRACP, Alexander G. Heriot, MD FRCS (Gen.), FRCSEd, FRACS

Erschienen in: Annals of Surgical Oncology | Ausgabe 11/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Advances in the management of rectal cancer have resulted in an increased application of multimodal therapy with the aim of tailoring therapy to individual patients. Complete pathological response (pCR) is associated with improved survival and may be potentially managed without radical surgical resection. Over the last decade, there has been increasing interest in the ability of functional imaging to predict complete response to treatment. The aim of this review was to assess the role of 18F-flurordeoxyglucose positron emission tomography (FDG-PET) in prediction of pCR and prognosis in resectable locally advanced rectal cancer.

Methods

A search of the MEDLINE and Embase databases was conducted, and a systematic review of the literature investigating positron emission tomography (PET) in the prediction of pCR and survival in rectal cancer was performed.

Results

Seventeen series assessing PET prediction of pCR were included in the review. Seven series assessed postchemoradiation SUVmax, which was significantly different between response groups in all six studies that assessed this. Nine series assessed the response index (RI) for SUVmax, which was significantly different between response groups in seven series. Thirteen studies investigated PET response for prediction of survival. Metabolic complete response assessed by SUV2max or visual response and RISUVmax showed strong associations with disease-free survival (DFS) and overall survival (OS).

Conclusion

SUV2max and RISUVmax appear to be useful FDG-PET markers for prediction of pCR and these parameters also show strong associations with DFS and OS. FDG-PET may have a role in outcome prediction in patients with advanced rectal cancer.
Literatur
1.
Zurück zum Zitat Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National cancer institute of the United States, National cancer institute of Canada. J Natl Cancer Inst. 2000;92(3):205–16.PubMedCrossRef Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National cancer institute of the United States, National cancer institute of Canada. J Natl Cancer Inst. 2000;92(3):205–16.PubMedCrossRef
2.
Zurück zum Zitat van der Paardt MP, Zagers MB, Beets-Tan RG, Stoker J, Bipat S. Patients who undergo preoperative chemoradiotherapy for locally advanced rectal cancer restaged by using diagnostic MR imaging: a systematic review and meta-analysis. Radiology. 2013;269(1):101–12.PubMedCrossRef van der Paardt MP, Zagers MB, Beets-Tan RG, Stoker J, Bipat S. Patients who undergo preoperative chemoradiotherapy for locally advanced rectal cancer restaged by using diagnostic MR imaging: a systematic review and meta-analysis. Radiology. 2013;269(1):101–12.PubMedCrossRef
3.
Zurück zum Zitat Larson SM. Cancer or inflammation? A holy grail for nuclear medicine. J Nucl Med. 1994;35(10):1653–5.PubMed Larson SM. Cancer or inflammation? A holy grail for nuclear medicine. J Nucl Med. 1994;35(10):1653–5.PubMed
4.
Zurück zum Zitat Engenhart R, Kimmig BN, Strauss LG, et al. Therapy monitoring of presacral recurrences after high-dose irradiation: value of PET, CT, CEA and pain score. Strahlenther Onkol. 1992;168(4):203–12.PubMed Engenhart R, Kimmig BN, Strauss LG, et al. Therapy monitoring of presacral recurrences after high-dose irradiation: value of PET, CT, CEA and pain score. Strahlenther Onkol. 1992;168(4):203–12.PubMed
5.
Zurück zum Zitat Pucciarelli S, De Paoli A, Guerrieri M, et al. Local excision after preoperative chemoradiotherapy for rectal cancer: results of a multicenter phase II clinical trial. Dis Colon Rectum. 2013;56(12):1349–56.PubMedCrossRef Pucciarelli S, De Paoli A, Guerrieri M, et al. Local excision after preoperative chemoradiotherapy for rectal cancer: results of a multicenter phase II clinical trial. Dis Colon Rectum. 2013;56(12):1349–56.PubMedCrossRef
6.
Zurück zum Zitat Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240(4):711–7.PubMedPubMedCentral Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240(4):711–7.PubMedPubMedCentral
7.
Zurück zum Zitat Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11(9):835–44.PubMedCrossRef Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11(9):835–44.PubMedCrossRef
8.
Zurück zum Zitat Bipat S, Glas AS, Slors FJ, Zwinderman AH, Bossuyt PM, Stoker J. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging—a meta-analysis. Radiology. 2004;232(3):773–83.PubMedCrossRef Bipat S, Glas AS, Slors FJ, Zwinderman AH, Bossuyt PM, Stoker J. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging—a meta-analysis. Radiology. 2004;232(3):773–83.PubMedCrossRef
9.
Zurück zum Zitat Valentini V, van Stiphout RG, Lammering G, et al. Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol. 2011;29(23):3163–72.PubMedCrossRef Valentini V, van Stiphout RG, Lammering G, et al. Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol. 2011;29(23):3163–72.PubMedCrossRef
10.
Zurück zum Zitat Bampo C, Alessi A, Fantini S, et al. Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation? Oncology. 2013;84(4):191–9.PubMedCrossRef Bampo C, Alessi A, Fantini S, et al. Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation? Oncology. 2013;84(4):191–9.PubMedCrossRef
11.
Zurück zum Zitat Capirci C, Rubello D, Pasini F, et al. The role of dual-time combined 18-fluorideoxyglucose positron emission tomography and computed tomography in the staging and restaging workup of locally advanced rectal cancer, treated with preoperative chemoradiation therapy and radical surgery. Int J Radiat Oncol Biol Phys. 2009;74(5):1461–9.PubMedCrossRef Capirci C, Rubello D, Pasini F, et al. The role of dual-time combined 18-fluorideoxyglucose positron emission tomography and computed tomography in the staging and restaging workup of locally advanced rectal cancer, treated with preoperative chemoradiation therapy and radical surgery. Int J Radiat Oncol Biol Phys. 2009;74(5):1461–9.PubMedCrossRef
12.
Zurück zum Zitat Cho YB, Chun HK, Kim MJ, et al. Accuracy of MRI and 18F-FDG PET/CT for restaging after preoperative concurrent chemoradiotherapy for rectal cancer. World J Surg. 2009;33(12):2688–94.PubMedCrossRef Cho YB, Chun HK, Kim MJ, et al. Accuracy of MRI and 18F-FDG PET/CT for restaging after preoperative concurrent chemoradiotherapy for rectal cancer. World J Surg. 2009;33(12):2688–94.PubMedCrossRef
13.
Zurück zum Zitat Goldberg N, Kundel Y, Purim O, et al. Early prediction of histopathological response of rectal tumors after one week of preoperative radiochemotherapy using 18 F-FDG PET-CT imaging. A prospective clinical study. Radiat Oncol. 2012;7:124.PubMedCrossRefPubMedCentral Goldberg N, Kundel Y, Purim O, et al. Early prediction of histopathological response of rectal tumors after one week of preoperative radiochemotherapy using 18 F-FDG PET-CT imaging. A prospective clinical study. Radiat Oncol. 2012;7:124.PubMedCrossRefPubMedCentral
14.
Zurück zum Zitat Guillem JG, Ruby JA, Leibold T, et al. Neither FDG-PET Nor CT can distinguish between a pathological complete response and an incomplete response after neoadjuvant chemoradiation in locally advanced rectal cancer: a prospective study. Ann Surg. 2013;258(2):289–95.PubMedCrossRef Guillem JG, Ruby JA, Leibold T, et al. Neither FDG-PET Nor CT can distinguish between a pathological complete response and an incomplete response after neoadjuvant chemoradiation in locally advanced rectal cancer: a prospective study. Ann Surg. 2013;258(2):289–95.PubMedCrossRef
15.
Zurück zum Zitat Hur H, Kim NK, Yun M, et al. 18Fluoro-deoxy-glucose positron emission tomography in assessing tumor response to preoperative chemoradiation therapy for locally advanced rectal cancer. J Surg Oncol. 2011;103(1):17–24.PubMedCrossRef Hur H, Kim NK, Yun M, et al. 18Fluoro-deoxy-glucose positron emission tomography in assessing tumor response to preoperative chemoradiation therapy for locally advanced rectal cancer. J Surg Oncol. 2011;103(1):17–24.PubMedCrossRef
16.
Zurück zum Zitat Kalff V, Ware R, Heriot A, Chao M, Drummond E, Hicks RJ. Radiation changes do not interfere with postchemoradiation restaging of patients with rectal cancer by FDG PET/CT before curative surgical therapy. Int J Radiat Oncol Biol Phys. 2009;74(1):60–6.PubMedCrossRef Kalff V, Ware R, Heriot A, Chao M, Drummond E, Hicks RJ. Radiation changes do not interfere with postchemoradiation restaging of patients with rectal cancer by FDG PET/CT before curative surgical therapy. Int J Radiat Oncol Biol Phys. 2009;74(1):60–6.PubMedCrossRef
17.
Zurück zum Zitat Kim JW, Kim HC, Park JW, et al. Predictive value of (18)FDG PET-CT for tumour response in patients with locally advanced rectal cancer treated by preoperative chemoradiotherapy. Int J Colorectal Dis. 2013;28(9):1217–24.PubMedCrossRef Kim JW, Kim HC, Park JW, et al. Predictive value of (18)FDG PET-CT for tumour response in patients with locally advanced rectal cancer treated by preoperative chemoradiotherapy. Int J Colorectal Dis. 2013;28(9):1217–24.PubMedCrossRef
18.
Zurück zum Zitat Konski A, Hoffman J, Sigurdson E, et al. Can molecular imaging predict response to preoperative chemoradiation in patients with rectal cancer? A fox chase cancer center prospective experience. Semin Oncol. 2005;32 Suppl. 9:S63–7.PubMedCrossRef Konski A, Hoffman J, Sigurdson E, et al. Can molecular imaging predict response to preoperative chemoradiation in patients with rectal cancer? A fox chase cancer center prospective experience. Semin Oncol. 2005;32 Suppl. 9:S63–7.PubMedCrossRef
19.
Zurück zum Zitat Kristiansen C, Loft A, Berthelsen AK, et al. PET/CT and histopathologic response to preoperative chemoradiation therapy in locally advanced rectal cancer. Dis Colon Rectum. 2008;51(1):21–5.PubMedCrossRef Kristiansen C, Loft A, Berthelsen AK, et al. PET/CT and histopathologic response to preoperative chemoradiation therapy in locally advanced rectal cancer. Dis Colon Rectum. 2008;51(1):21–5.PubMedCrossRef
20.
Zurück zum Zitat Lambrecht M, Deroose C, Roels S, et al. The use of FDG-PET/CT and diffusion-weighted magnetic resonance imaging for response prediction before, during and after preoperative chemoradiotherapy for rectal cancer. Acta Oncol. 2010;49(7):956–63.PubMedCrossRef Lambrecht M, Deroose C, Roels S, et al. The use of FDG-PET/CT and diffusion-weighted magnetic resonance imaging for response prediction before, during and after preoperative chemoradiotherapy for rectal cancer. Acta Oncol. 2010;49(7):956–63.PubMedCrossRef
21.
Zurück zum Zitat Lee SJ, Kim JG, Lee SW, et al. Clinical implications of initial FDG-PET/CT in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Cancer Chemother Pharmacol. 2013;71(5):1201–7.PubMedCrossRef Lee SJ, Kim JG, Lee SW, et al. Clinical implications of initial FDG-PET/CT in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Cancer Chemother Pharmacol. 2013;71(5):1201–7.PubMedCrossRef
22.
Zurück zum Zitat Mak D, Joon DL, Chao M, et al. The use of PET in assessing tumor response after neoadjuvant chemoradiation for rectal cancer. Radiother Oncol. 2010;97(2):205–11.PubMedCrossRef Mak D, Joon DL, Chao M, et al. The use of PET in assessing tumor response after neoadjuvant chemoradiation for rectal cancer. Radiother Oncol. 2010;97(2):205–11.PubMedCrossRef
23.
Zurück zum Zitat Martoni AA, di Fabio F, Pinto C, et al. Prospective study on the FDG-PET/CT predictive and prognostic values in patients treated with neoadjuvant chemoradiation therapy and radical surgery for locally advanced rectal cancer. Ann Oncol. 2011;22(3):650–6.PubMedCrossRef Martoni AA, di Fabio F, Pinto C, et al. Prospective study on the FDG-PET/CT predictive and prognostic values in patients treated with neoadjuvant chemoradiation therapy and radical surgery for locally advanced rectal cancer. Ann Oncol. 2011;22(3):650–6.PubMedCrossRef
24.
Zurück zum Zitat Palma P, Conde-Muino R, Rodriguez-Fernandez A, et al. The value of metabolic imaging to predict tumour response after chemoradiation in locally advanced rectal cancer. Radiat Oncol. 2010;5(1):119.PubMedCrossRefPubMedCentral Palma P, Conde-Muino R, Rodriguez-Fernandez A, et al. The value of metabolic imaging to predict tumour response after chemoradiation in locally advanced rectal cancer. Radiat Oncol. 2010;5(1):119.PubMedCrossRefPubMedCentral
25.
Zurück zum Zitat Shanmugan S, Arrangoiz R, Nitzkorski JR, et al. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using (18)FDG-PET/CT. Ann Surg Oncol. 2012;19(7): 2178–85.PubMedCrossRef Shanmugan S, Arrangoiz R, Nitzkorski JR, et al. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using (18)FDG-PET/CT. Ann Surg Oncol. 2012;19(7): 2178–85.PubMedCrossRef
26.
Zurück zum Zitat Sun W, Xu J, Hu W, Zhang Z, Shen W. The role of sequential 18(F)-FDG PET/CT in predicting tumour response after preoperative chemoradiation for rectal cancer. Colorectal Dis. 2013;15(5):e231–8.PubMedCrossRef Sun W, Xu J, Hu W, Zhang Z, Shen W. The role of sequential 18(F)-FDG PET/CT in predicting tumour response after preoperative chemoradiation for rectal cancer. Colorectal Dis. 2013;15(5):e231–8.PubMedCrossRef
27.
Zurück zum Zitat Avallone A, Aloj L, Caraco C, et al. Early FDG PET response assessment of preoperative radiochemotherapy in locally advanced rectal cancer: correlation with long-term outcome. Eur J Nucl Med Mol Imaging. 2012;39(12):1848–57.PubMedCrossRef Avallone A, Aloj L, Caraco C, et al. Early FDG PET response assessment of preoperative radiochemotherapy in locally advanced rectal cancer: correlation with long-term outcome. Eur J Nucl Med Mol Imaging. 2012;39(12):1848–57.PubMedCrossRef
28.
Zurück zum Zitat Calvo FA, Domper M, Matute R, et al. 18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys. 2004;58(2):528–35.PubMedCrossRef Calvo FA, Domper M, Matute R, et al. 18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys. 2004;58(2):528–35.PubMedCrossRef
29.
Zurück zum Zitat Calvo FA, Sole CV, de la Mata D, et al. (1)(8)F-FDG PET/CT-based treatment response evaluation in locally advanced rectal cancer: a prospective validation of long-term outcomes. Eur J Nucl Med Mol Imaging. 2013;40(5):657–67.PubMedCrossRef Calvo FA, Sole CV, de la Mata D, et al. (1)(8)F-FDG PET/CT-based treatment response evaluation in locally advanced rectal cancer: a prospective validation of long-term outcomes. Eur J Nucl Med Mol Imaging. 2013;40(5):657–67.PubMedCrossRef
30.
Zurück zum Zitat Capirci C, Rubello D, Chierichetti F, et al. Long-term prognostic value of 18F-FDG PET in patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy. AJR Am J Roentgenol. 2006;187(2):W202–8.PubMedCrossRef Capirci C, Rubello D, Chierichetti F, et al. Long-term prognostic value of 18F-FDG PET in patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy. AJR Am J Roentgenol. 2006;187(2):W202–8.PubMedCrossRef
31.
Zurück zum Zitat Guillem JG, Moore HG, Akhurst T, et al. Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: A means for determining longterm outcomes of rectal cancer. J Am Coll Surg. 2004;199(1):1–7.PubMedCrossRef Guillem JG, Moore HG, Akhurst T, et al. Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: A means for determining longterm outcomes of rectal cancer. J Am Coll Surg. 2004;199(1):1–7.PubMedCrossRef
32.
Zurück zum Zitat Konski A, Li T, Sigurdson E, et al. Use of molecular imaging to predict clinical outcome in patients with rectal cancer after preoperative chemotherapy and radiation. Int J Radiat Oncol Biol Phys. 2009;74(1):55–9.PubMedCrossRefPubMedCentral Konski A, Li T, Sigurdson E, et al. Use of molecular imaging to predict clinical outcome in patients with rectal cancer after preoperative chemotherapy and radiation. Int J Radiat Oncol Biol Phys. 2009;74(1):55–9.PubMedCrossRefPubMedCentral
33.
Zurück zum Zitat Nakagawa K, Yamashita H, Nakamura N, et al. Preoperative radiation response evaluated by 18-fluorodeoxyglucose positron emission tomography predicts survival in locally advanced rectal cancer. Dis Colon Rectum. 2008;51(7):1055–60.PubMedCrossRef Nakagawa K, Yamashita H, Nakamura N, et al. Preoperative radiation response evaluated by 18-fluorodeoxyglucose positron emission tomography predicts survival in locally advanced rectal cancer. Dis Colon Rectum. 2008;51(7):1055–60.PubMedCrossRef
34.
Zurück zum Zitat Oku S, Nakagawa K, Momose T, et al. FDG-PET after radiotherapy is a good prognostic indicator of rectal cancer. Ann Nucl Med. 2002;16(6):409–16.PubMedCrossRef Oku S, Nakagawa K, Momose T, et al. FDG-PET after radiotherapy is a good prognostic indicator of rectal cancer. Ann Nucl Med. 2002;16(6):409–16.PubMedCrossRef
35.
Zurück zum Zitat Ruby JA, Leibold T, Akhurst TJ, et al. FDG-PET assessment of rectal cancer response to neoadjuvant chemoradiotherapy is not associated with long-term prognosis: a prospective evaluation. Dis Colon Rectum. 2012;55(4):378–86.PubMedCrossRef Ruby JA, Leibold T, Akhurst TJ, et al. FDG-PET assessment of rectal cancer response to neoadjuvant chemoradiotherapy is not associated with long-term prognosis: a prospective evaluation. Dis Colon Rectum. 2012;55(4):378–86.PubMedCrossRef
36.
Zurück zum Zitat Yeung JMC, Kalff V, Hicks RJ, et al. Metabolic response of rectal cancer assessed by 18-FDG PET following chemoradiotherapy is prognostic for patient outcome. Dis Colon Rectum. 2011;54(5):518–25.PubMedCrossRef Yeung JMC, Kalff V, Hicks RJ, et al. Metabolic response of rectal cancer assessed by 18-FDG PET following chemoradiotherapy is prognostic for patient outcome. Dis Colon Rectum. 2011;54(5):518–25.PubMedCrossRef
37.
Zurück zum Zitat Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European organization for research and treatment of cancer (EORTC) PET study group. Eur J Cancer. 1999;35(13):1773–82.PubMedCrossRef Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European organization for research and treatment of cancer (EORTC) PET study group. Eur J Cancer. 1999;35(13):1773–82.PubMedCrossRef
38.
Zurück zum Zitat Lowe VJ, Boyd JH, Dunphy FR, et al. Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol. 2000;18(3):651–8.PubMed Lowe VJ, Boyd JH, Dunphy FR, et al. Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol. 2000;18(3):651–8.PubMed
39.
Zurück zum Zitat Perez RO, Habr-Gama A, Gama-Rodrigues J, et al. Accuracy of positron emission tomography/computed tomography and clinical assessment in the detection of complete rectal tumor regression after neoadjuvant chemoradiation: long-term results of a prospective trial (National Clinical Trial 00254683). Cancer. 2012;118(14):3501–11.PubMedCrossRef Perez RO, Habr-Gama A, Gama-Rodrigues J, et al. Accuracy of positron emission tomography/computed tomography and clinical assessment in the detection of complete rectal tumor regression after neoadjuvant chemoradiation: long-term results of a prospective trial (National Clinical Trial 00254683). Cancer. 2012;118(14):3501–11.PubMedCrossRef
40.
Zurück zum Zitat Kalady MF, de Campos-Lobato LF, Stocchi L, et al. Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann Surg. 2009;250(4):582–9.PubMed Kalady MF, de Campos-Lobato LF, Stocchi L, et al. Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann Surg. 2009;250(4):582–9.PubMed
41.
Zurück zum Zitat Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(1):057307. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(1):057307.
42.
Zurück zum Zitat van Stiphout RG, Lammering G, Buijsen J, et al. Development and external validation of a predictive model for pathological complete response of rectal cancer patients including sequential PET-CT imaging. Radiother Oncol. 2011;98(1):126–33.PubMedCrossRef van Stiphout RG, Lammering G, Buijsen J, et al. Development and external validation of a predictive model for pathological complete response of rectal cancer patients including sequential PET-CT imaging. Radiother Oncol. 2011;98(1):126–33.PubMedCrossRef
Metadaten
Titel
Systematic Review of FDG-PET Prediction of Complete Pathological Response and Survival in Rectal Cancer
verfasst von
Sameer Memon, FRACS
A. Craig Lynch, MMedSci, FRACS, FCSSANZ, FASCRS (INT)
Timothy Akhurst, MD, MBBS
Samuel Y. Ngan, MBBS
Satish K. Warrier, MS, FRACS
Michael Michael, MD, FRACP
Alexander G. Heriot, MD FRCS (Gen.), FRCSEd, FRACS
Publikationsdatum
01.10.2014
Verlag
Springer US
Erschienen in
Annals of Surgical Oncology / Ausgabe 11/2014
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-3753-z

Weitere Artikel der Ausgabe 11/2014

Annals of Surgical Oncology 11/2014 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.